Choose Your Country or Region

Anti-Cdk7 Rabbit Antibody [K16B2]

Catalog No.: F4040

Application: Reactivity: Mouse, Rat, Human

Usage Information

Dilution
WB1:1000 IP1:30 IHC1:100 FCM1:50

Application
WB, IP, IHC, FCM

Reactivity
Mouse, Rat, Human

Source
Rabbit

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
39 kDa 39 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight.

Datasheet & SDS

Biological Description

Specificity
Anti-Cdk7 Rabbit Antibody [K16B2] detects endogenous levels of total Cdk7 protein.

Clone
K16B2

Synonym(s)
CAK, CAK1, CDKN7, MO15, STK1, CDK7, Cyclin-dependent kinase 7, 39 kDa protein kinase, CDK-activating kinase 1, Cell division protein kinase 7, Serine/threonine-protein kinase 1, TFIIH basal transcription factor complex kinase subunit, p39 Mo15

Background
Cyclin-dependent kinase 7 (CDK7) is a pivotal kinase that serves dual functions central to cell cycle control and transcription regulation. CDK7 forms an active complex with cyclin H and MAT1, collectively known as the CDK-activating kinase (CAK) complex, which phosphorylates and activates several key cyclin-dependent kinases (CDKs) such as CDK1, CDK2, CDK4, and CDK6 to promote orderly progression through the G1, S, G2, and M phases of the cell cycle. CDK7 possesses a typical kinase fold with an activation segment (T-loop) where dual phosphorylation at conserved residues (Thr170 and Ser164) modulates its kinase activity and substrate specificity. CDK7 is also an essential component of the general transcription factor TFIIH, phosphorylating the C-terminal domain (CTD) of RNA polymerase II at Ser5 and Ser7 to facilitate transcription initiation, promoter-proximal pausing, elongation, RNA processing, and chromatin modification. Regulation of CDK7 activity occurs through phosphorylation of itself and cyclin H, complex assembly with MAT1, and interactions with transcriptional machinery and other CDKs such as CDK9. Dysregulation of CDK7 contributes to cancer progression.

Background

Cyclin-dependent kinase 7 (CDK7) is a pivotal kinase that serves dual functions central to cell cycle control and transcription regulation. CDK7 forms an active complex with cyclin H and MAT1, collectively known as the CDK-activating kinase (CAK) complex, which phosphorylates and activates several key cyclin-dependent kinases (CDKs) such as CDK1, CDK2, CDK4, and CDK6 to promote orderly progression through the G1, S, G2, and M phases of the cell cycle. CDK7 possesses a typical kinase fold with an activation segment (T-loop) where dual phosphorylation at conserved residues (Thr170 and Ser164) modulates its kinase activity and substrate specificity. CDK7 is also an essential component of the general transcription factor TFIIH, phosphorylating the C-terminal domain (CTD) of RNA polymerase II at Ser5 and Ser7 to facilitate transcription initiation, promoter-proximal pausing, elongation, RNA processing, and chromatin modification. Regulation of CDK7 activity occurs through phosphorylation of itself and cyclin H, complex assembly with MAT1, and interactions with transcriptional machinery and other CDKs such as CDK9. Dysregulation of CDK7 contributes to cancer progression.

References
https://pubmed.ncbi.nlm.nih.gov/40223539/ https://pubmed.ncbi.nlm.nih.gov/39097586/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%